Antiarrhythmic Drugs: Mechanisms of Antiarrhythmic and Proarrhythmic Actions
W. Haverkamp · Günter Breithardt · G. Hindricks · Martin Borggrefe · John A. Camm · Mohammad Shenasa
2012-12 · Springer Science & Business Media
El. knyga
410
Puslapiai
reportĮvertinimai ir apžvalgos nepatvirtinti. Sužinokite daugiau
Apie šią el. knygą
The past 10 years have seen a remarkable change in the approach to cardiac arrhythmias, from a position of confidence and a feeling of well-being about pharmacological treatment to a situation in which there is now marked uncertainty and general apprehension about the role of antiarrhythmic drugs. Until relatively recently the prevailing concept in antiarrhythmic therapy was that arrhythmias could be controlled by drugs which slowed conduction or suppressed automaticity, goals well served by the sodium channel-blocking drugs and glycosides. Drug re search was based largely on the development of agents mimicking those already available, but with greater efficacy, fewer side effects or a more favourable phar macokinetic profile. The CAST trial stands out as a landmark in the evolution of arrhytmia manage ment; rarely has a single trial had such a profound impact not only on clinical prac tice, but also on the whole approach of those involved in the research, development and regulation of antiarrhythmic drugs. The results of the CAST trial, designed to redress the shortcomings of earlier trials which had failed to demonstrate the anticipated improvement in mortality post-myocardial infarction with the use of class I agents, are well known. The CAST and CAST II showed an increase in mor tality associated with the active agent (encainide, flecainide or morizicine) com pared to placebo treatment. They firmly established the potential danger in the use of class I drugs.
Įvertinti šią el. knygą
Pasidalykite savo nuomone.
Skaitymo informacija
Išmanieji telefonai ir planšetiniai kompiuteriai
Įdiekite „Google Play“ knygų programą, skirtą „Android“ ir „iPad“ / „iPhone“. Ji automatiškai susinchronizuojama su paskyra ir jūs galite skaityti tiek prisijungę, tiek neprisijungę, kad ir kur būtumėte.
Nešiojamieji ir staliniai kompiuteriai
Galite klausyti garsinių knygų, įsigytų sistemoje „Google Play“ naudojant kompiuterio žiniatinklio naršyklę.
El. knygų skaitytuvai ir kiti įrenginiai
Jei norite skaityti el. skaitytuvuose, pvz., „Kobo eReader“, turite atsisiųsti failą ir perkelti jį į įrenginį. Kad perkeltumėte failus į palaikomus el. skaitytuvus, vadovaukitės išsamiomis pagalbos centro instrukcijomis.
